RxDoctor Payments DataLook up a doctor →

Sandra El-Hachem, MD

Gastroenterology · Pittsburgh, PANPI 1851583108

Payments from drug & device makers

$817,493in general payments, 2019–2025

Across 482 payments — averaging $1696.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$344K
  • Takeda Pharmaceuticals U.S.A., Inc.$156K
  • Johnson & Johnson$139K
  • Janssen Scientific Affairs, LLC$43K
  • Pfizer$39K
  • Janssen Research & Development, LLC$39K
  • plus $57K from 11 others

What the payments were for

  • Consulting fees$14,2503%
  • Speaking & faculty fees$412,73487%
  • Travel & lodging$33,9467%
  • Food & beverage$10,8142%
  • Education$2700%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$817,493 in reported general payments places this provider in the 95th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$36,678
Medicare patients
189
Services billed
315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab67$1,809,528
Humira(Cf) PenAdalimumab95$830,163
EntyvioVedolizumab53$471,545
Skyrizi On-BodyRisankizumab-Rzaa16$336,012
RinvoqUpadacitinib13$147,817
Mesalamine58$36,903
Mesalamine ErMesalamine23$6,390
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates63$4,613
Balsalazide Disodium16$3,552
Mercaptopurine30$2,411
SutabSod Sulf/Pot Chloride/Mag Sulf11$1,731
Sulfasalazine24$1,553
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine28$1,394
LoperamideLoperamide Hcl19$1,287
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl48$924

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$138,964$1,809,52867 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$156,119$471,54553 claims
AbbVieRinvoq$344,454$147,81713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →